Sweden's Q-linea Q3 sales rise; signs new US healthcare agreement
Sweden's Q-linea Q3 sales rise; signs new US healthcare agreement
Overview
Sweden infection diagnostics firm's Q3 net sales grew yr/yr, but contracted instrument sales declined
Operating loss for Q3 narrowed compared to last year
Company signed US healthcare agreement and Premier, Inc. framework deal, but US adoption remains slow
Outlook
Company expects evaluation timelines to decrease as more real-world data is generated
Company anticipates further deployments in Europe later this year following positive evaluations
Q-linea expects to announce further product and menu expansions within 6-12 months
Result Drivers
US MARKET CONTRACTS - Co signed new US healthcare agreement and expanded with existing IDN customer in Q3
GROUP PURCHASING DEAL - National framework agreement with Premier, Inc. expected to reduce contracting timelines and increase visibility
CONSUMABLES USAGE - US consumables usage reached highest level in Q3 after expanded menu adoption
Company press release: ID:nMFN3MyWx2
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss |
| SEK 29.30 mln |
|
Q3 Adjusted Free Cash Flow |
| -SEK 34.30 mln |
|
Q3 EBIT |
| -SEK 30.60 mln |
|
Reuters Recommended Reads
Oct 28 - GE Healthcare Q3 profit beats estimates on advanced imaging segment
Oct 28 - Sweden's Fenix Outdoor Q3 sales rise on Nordic demand, Devold portfolio addition
Oct 29 - Sweden's Nolato Q3 profit slips on higher input costs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)